Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
Authors
Keywords
-
Journal
Medicina-Lithuania
Volume 55, Issue 12, Pages 754
Publisher
MDPI AG
Online
2019-11-22
DOI
10.3390/medicina55120754
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma
- (2019) K. Yamazaki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
- (2019) Mi Na Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF‐MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement
- (2019) Matteo Claudio Da Vià et al. ONCOLOGIST
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells
- (2017) Jing Li et al. Oncology Letters
- Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways
- (2016) Yu Wang et al. BMC CANCER
- PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
- (2016) Vivek Asati et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Leptin induces osteocalcin expression in ATDC5 cells through activation of the MAPK-ERK1/2 signaling pathway
- (2016) Yingchao Han et al. Oncotarget
- Genome-wide exploration of the molecular evolution and regulatory network of mitogen-activated protein kinase cascades upon multiple stresses in Brachypodium distachyon
- (2015) Min Jiang et al. BMC GENOMICS
- Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib
- (2015) Andrea Casadei Gardini et al. EXPERT OPINION ON PHARMACOTHERAPY
- Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets
- (2015) Didier Meseure et al. Biomed Research International
- The Changing Landscape of Hepatocellular Carcinoma
- (2014) Erik S. Knudsen et al. AMERICAN JOURNAL OF PATHOLOGY
- BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
- (2014) C. Breunig et al. CLINICAL CANCER RESEARCH
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
- (2014) Thomas Knight et al. Frontiers in Oncology
- Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions
- (2013) Antonio Gnoni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Somatic changes in primary liver cancer in Russia: A pilot study
- (2013) Olga Kalinina et al. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Overexpression of nuclear NHERF1 in advanced colorectal cancer: Association with hypoxic microenvironment and tumor invasive phenotype
- (2012) Andrea Malfettone et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
- (2012) Antonella De Luca et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Biomarkers for early diagnosis of hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET ONCOLOGY
- BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy
- (2012) M Colombino et al. Cell Death & Disease
- Multivariate Analysis of Several Molecular Markers and Clinicopathological Features in Postoperative Prognosis of Hepatocellular Carcinoma
- (2011) Qiang Zuo et al. Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology
- Estrogenic effect of the MEK1 inhibitor PD98059 on endogenous estrogen receptor alpha and beta
- (2011) Cândida Z. Cotrim et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
- (2011) M Caraglia et al. Cell Death & Disease
- High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice
- (2010) D. Santini et al. ANNALS OF ONCOLOGY
- EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence
- (2010) Anna Elisa Quatrale Frontiers in Bioscience-Landmark
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
- (2008) S. A. Lang et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
- (2007) Klaus Juergen Schmitz et al. JOURNAL OF HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started